The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Ferric maltol (Feraccru®) has been rejected for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD). The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance.
Hydrocortisone (Plenadren®) has been rejected for use in the treatment of adrenal insufficiency in adults. The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - November 2016||Drug Safety Update - December 2016 »|